{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-067649","form_type":"8-K","ticker":"SNGX","cik":"0000812796","company_name":"SOLIGENIX, INC.","filed_at":"2026-05-28T21:21:17+00:00","discovered_at":"2026-05-28T21:22:00.321772+00:00","generated_at":"2026-05-28T21:24:16.438263+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Soligenix increases at-market offering by $2.96M, total now up to $6.4M","bullets":["Filed prospectus supplement on May 28, 2026, increasing shares issuable under Sales Agreement with Rodman & Renshaw by $2,956,000.","Prior sales under the agreement totaled approximately $3,445,000; combined maximum now $6,401,000.","Common stock (SNGX) offered on Nasdaq; legal opinion from Duane Morris LLP filed as Exhibit 5.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-067649","json":"https://secwatch.observer/filing/0001104659-26-067649.json","markdown":"https://secwatch.observer/filing/0001104659-26-067649.md","text":"https://secwatch.observer/filing/0001104659-26-067649.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/812796/000110465926067649/0001104659-26-067649-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/812796/000110465926067649/sngx-20260528x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T21:24:16.438263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001193125-26-251789","ticker":"GIPR","company_name":"GENERATION INCOME PROPERTIES, INC.","filed_at":"2026-06-01T21:27:59+00:00","headline":"Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit","event_type":"other_material","sec_items":["1.01","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251789","json":"https://secwatch.observer/filing/0001193125-26-251789.json","markdown":"https://secwatch.observer/filing/0001193125-26-251789.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/0001193125-26-251789-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/gipr-20260528.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-069016","ticker":"MUX","company_name":"McEwen Inc.","filed_at":"2026-06-01T21:14:20+00:00","headline":"McEwen receives $49.4M dividend from Minera Santa Cruz; total 2026 dividends now $58.2M","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069016","json":"https://secwatch.observer/filing/0001104659-26-069016.json","markdown":"https://secwatch.observer/filing/0001104659-26-069016.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/314203/000110465926069016/0001104659-26-069016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/314203/000110465926069016/tm2616562d1_8ka.htm"},"side_by_side_evidence":null},{"accession":"0001449794-26-000012","ticker":"EMYB","company_name":"Embassy Bancorp, Inc.","filed_at":"2026-06-01T20:37:17+00:00","headline":"Embassy Bancorp expands stock repurchase program by additional $5M","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001449794-26-000012","json":"https://secwatch.observer/filing/0001449794-26-000012.json","markdown":"https://secwatch.observer/filing/0001449794-26-000012.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1449794/000144979426000012/0001449794-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1449794/000144979426000012/emyb-20260601x8k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063531","ticker":"CTXR","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2026-06-01T20:30:19+00:00","headline":"Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063531","json":"https://secwatch.observer/filing/0001213900-26-063531.json","markdown":"https://secwatch.observer/filing/0001213900-26-063531.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/0001213900-26-063531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/ea0292904-8k_citius.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063530","ticker":"CTOR","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2026-06-01T20:30:18+00:00","headline":"Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063530","json":"https://secwatch.observer/filing/0001213900-26-063530.json","markdown":"https://secwatch.observer/filing/0001213900-26-063530.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026063530/0001213900-26-063530-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026063530/ea0292903-8k_citius.htm"},"side_by_side_evidence":null},{"accession":"0001636282-26-000075","ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-06-01T20:01:39+00:00","headline":"Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-26-000075","json":"https://secwatch.observer/filing/0001636282-26-000075.json","markdown":"https://secwatch.observer/filing/0001636282-26-000075.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/0001636282-26-000075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/syre-20260529.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063481","ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2026-06-01T20:01:27+00:00","headline":"Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063481","json":"https://secwatch.observer/filing/0001213900-26-063481.json","markdown":"https://secwatch.observer/filing/0001213900-26-063481.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000121390026063481/0001213900-26-063481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000121390026063481/ea0292876-8k_oruka.htm"},"side_by_side_evidence":null},{"accession":"0001606268-26-000032","ticker":"VIASP","company_name":"Via Renewables, Inc.","filed_at":"2026-06-01T19:06:57+00:00","headline":"Via Renewables to redeem all 1,884,935 shares of its 8.75% Series A Preferred at $25.00 per share plus dividends","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001606268-26-000032","json":"https://secwatch.observer/filing/0001606268-26-000032.json","markdown":"https://secwatch.observer/filing/0001606268-26-000032.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606268/000160626826000032/0001606268-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606268/000160626826000032/spke-20260601.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}